The ASCO Annual Meeting, presented online on June 4-8, brings together one of the largest audiences to present the latest and most innovative research in oncology.
Three abstracts submitted by COTA and various collaborators have been accepted for publication at this year’s meeting. This research addresses a range of topics including:
Study of the real-world outcomes of patients with metastatic pancreatic cancer
Investigation of real-world treatment patterns and outcomes of patients with advanced non-small cell lung cancer
Performance of real-world overall survival among five RWD partners following a standardized analytic plan
These abstracts demonstrate COTA’s commitment to working with all stakeholders – across healthcare – to bring clarity to cancer care with real-world data. Key collaborators from University of Texas Southwestern Medical Center, Cleveland Clinic, Friends of Cancer Research, and FDA contributed to this work.
Abstracts selected for publication:
Due to lack of enrollment of representative patients in clinical trials and in the absence of a comparative clinical trial, real-world experience with chemotherapy regimens provide critical insights on the outcome of treatments.
Our study showed that in a real-world population of patients with aNSCLC and driver mutations, patients treated with chemo+IO combination had longer rwPFS and rwTTNT as compared to those treated with chemo alone or IO monotherapy.
The systematic evaluation of reproducibility and performance of rwOS across five real-world cohorts and the impact of implementing consistent eligibility criteria and methods was useful to understand the consistency of results in real-world populations and relationship between treatments and outcomes in the absence of randomization.